Aspen Pharmacare Holdings EBIT

The latest EBIT for APNHY is $6.2B as of December 2025. That compares with $8.7B in the prior-year period — down 28.3% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Aspen Pharmacare Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, APNHY's EBIT moved from $8.7B to $6.2B — a 28.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Aspen Pharmacare Holdings's operating scale or balance-sheet position.

Against Healthcare companies, APNHY currently prints $6.2B for EBIT, while the sector average sits near $23B. That is roughly 73.1% below the sector mean. Large gaps often invite a closer look at Aspen Pharmacare Holdings's growth, margins, and balance sheet.

A EBIT figure of $6.2B for APNHY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting APNHY's EBIT ($6.2B), review year-over-year change from $8.7B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.